News

When the GUARD-AF study had first started enrolling patients in 2019, researchers had planned to include 52,000 patients. The Covid-19 pandemic dashed those plans, and the study ended up ...
The analysis period corresponded to the initial launch of the Zio monitor and included 14-day prescriptions between May 2022 and September 2023, comprising 7,433 Zio monitors and 1,336,391 Zio XT ...
Heart monitor Average typical use (days) Longest typical use (days) Number of ECG channels (typical use) Physician over-reading Rhythm analysis Ref. Zio® Patch: 7–10: 14: 1: Yes: Proprietary at ...
iRhythm’s next-generation Zio® monitor demonstrated longer wear duration and analyzable time compared to the prior generation Zio® XT device.Longer wear duration and analyzable time may ...
iRhythm's Zio XT wearable heart monitor raises AFib diagnoses by 52%, but doesn't reduce stroke hospitalisations in GUARD-AF trial.
This note discusses the important advancements of the iRhythm (IRTC) Zio Monitor. iRhythm is a constituent of the Robo Global Healthcare Technology and Innovation Index (HTEC).
Ambulatory cardiac monitors (ACM) enable heart rhythm monitoring for various durations, including Holter monitors (0–48 hours), long-term continuous monitoring (LTCM, 3–14 days), and external ...
SAN FRANCISCO - iRhythm Technologies, Inc. (NASDAQ:IRTC), a digital healthcare company, has revealed new research findings on the performance of its next-generation Zio monitor, a long-term ...
IRTC announces initial findings demonstrating the superior real-world performance of the next-generation Zio LTCM Monitor at the HRX 2024 meeting.
A number of substantial improvements to the 60-year-old concept of the Holter monitor have recently been developed. One promising advance is the Zio® Patch (iRhythm Technologies, Inc., CA, USA ...
The new Zio LTCM service demonstrated fewer early wear terminations, with data showing a wear time of less than 48 hours in 1.1% of Zio monitor services compared to 2.8% for Zio XT service.